With the approach of the influenza season, the number of influenza cases has risen significantly in many parts of the country recently. The CDC has issued an urgent reminder that the positive rate of influenza A virus has continued to climb, with more than 99% being influenza A. Influenza, as an acute respiratory infectious disease, is characterized by rapid spread and strong infectivity, bringing huge global public health pressure every year, especially posing a serious threat to children, the elderly and people with weakened immune functions.

Against this background, the demand for anti-influenza drugs is becoming more and more urgent. With the approaching launch of "Mapixavir", an anti-influenza innovative drug independently developed by JOINCARE (stock code: 600380), a new option may be available for influenza treatment in China. This new drug has attracted great attention in the industry with its remarkable efficacy, convenient dosing regimen and excellent safety, and has become a "rising star" in the field of anti-influenza.

Rapid and Effective Inhibition of Influenza Virus

Mapixavir, as the first cap-dependent endonuclease inhibitor in China, can effectively block the replication and spread of influenza virus, especially showing strong advantages in the treatment of influenza A. Compared with traditional anti-influenza drugs, the biggest highlight of Mapixavir is its "rapid onset and simple treatment course". After taking it, patients can quickly relieve symptoms and greatly shorten the time of virus replication.

Clinical trial results show that Mapixavir can effectively shorten the duration of influenza symptoms, especially in the treatment of influenza A and influenza B. Compared with the placebo group, the symptom relief time in influenza B patients was shortened by 31 hours, and the effect was particularly significant in the adolescent group, with a relief time shortened by 61 hours and no major adverse reactions, fully demonstrating its superiority in influenza treatment.

For Adolescent Patients, Safer and More Efficient

Adolescents are one of the high-risk groups for influenza. With the high incidence of influenza virus, the treatment needs of adolescent influenza patients are particularly urgent. Mapixavir can not only effectively relieve influenza symptoms, but also, due to its "good safety and strong tolerance", has become an ideal treatment option for adolescent patients.

In the latest clinical trial, the treatment effect of Mapixavir on adolescent influenza patients has been widely recognized. Compared with traditional drugs, the efficacy of Mapixavir is more significant, and the symptom relief time is greatly shortened. It has the characteristics of greater safety and effectiveness when used in the adolescent group.

Convenient Medication, Effective with a Single Dose

Unlike traditional anti-influenza drugs that usually require continuous multiple doses, one of the greatest advantages of Mapixavir is that "a single oral dose can achieve the treatment effect". Patients only need to take a single oral dose of 40mg or 80mg to effectively inhibit the influenza virus. This convenient dosing method significantly improves patient compliance and is especially suitable for modern people with a fast-paced life and a need to simplify the treatment process.

In addition, Mapixavir has "low drug resistance", which means that the risk of drug failure during treatment is low and can provide a long-lasting and effective curative effect. This characteristic undoubtedly provides patients with a safer and more sustainable treatment experience.

Mapixavir is about to be Launched, Attracting Capital Market Attention

The stock price of JOINCARE Pharmaceutical has risen significantly since December last year, especially performing well under the recent high incidence of influenza and the expectation of the new drug launch. Yesterday, the stock price rose sharply, with an intraday increase approaching 5%, hitting the largest increase in nearly a month. At the same time, the stock price of another company related to the anti-influenza drug supply chain, Hualan Biological, also rose by 2.6% simultaneously, showing the positive expectations of the capital market for the influenza-related industrial chain.

Analysts pointed out that the launch of Mapixavir will have a significant driving effect on the performance of JOINCARE Pharmaceutical. It is expected that the market share of JOINCARE Pharmaceutical in the anti-influenza field will increase significantly in the future, thus driving the growth of the company's overall performance.


This article is reprinted from: Xianning News Network.